New FDA Advisory Committee to Explore Genetic Metabolic Disease Drugs

The FDA has announced a new Genetic Metabolic Diseases Advisory Committee (GeMDAC) to help the agency explore the complex issues related to genetic metabolic disease drug development.
Source: Drug Industry Daily